NeuroSense Therapeutics Ltd.
News
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification
PR Newswire NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire CAMBRIDGE, Mass...\n more…
EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug
Benzinga NeuroSense Therapeutics is in advanced talks with major pharmaceutical companies for a strategic partnership to develop and commercialize its ALS drug, PrimeC. The company expects to receive terms by Q4 2024, but final agreements are not yet assured.\n more…
NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price
PR Newswire NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price NeuroSense Therapeutics Announces Private Placement with Senior Management...\n more…
NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial
PR Newswire NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial PR Newswire...\n more…
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Update
Ticker Report NeuroSense Therapeutics Ltd. (NASDAQ:NRSN - Get Free Report) saw a significant growth in short interest in June. As of June 30th, there was short interest totalling 17,900 shares, a growth of 121.0...\n more…
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
PR Newswire NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression NeuroSense's PARADIGM ALS...\n more…